- 121
- 13 127
GI Oncology Now
Приєднався 3 сер 2023
ESMO 2024 Key Highlights in Liver Cancer: LEAP-012 and IMbrave050 Discussion
Richard Finn, MD, of the Geffen School of Medicine at UCLA, provides an update on recent developments in hepatocellular carcinoma treatment (HCC), highlighting key findings from studies involving immune checkpoint inhibitors targeting CTLA-4 and PD-1 pathways. Dr. Finn explains how the inclusion of patients with main portal vein invasion impacts outcomes in overall survival.
Watch more video insights at www.docwirenews.com/page/gi-oncology-now.
Watch more video insights at www.docwirenews.com/page/gi-oncology-now.
Переглядів: 1
Відео
The HIMALAYA Study: STRIDE for uHCC Shows Beneficial 5-Year OS Results
Переглядів 11021 день тому
Lorenza Rimassa, MD, of Humanitas University, gives an overview of the phase 3 HIMALAYA study and its 5-year overall survival results that were presented at ESMO Congress 2024. The study examined tremelimumab plus durvalumab for the treatment of unresectable hepatocellular carcinoma, and found the combination to significantly improve overall survival over sorafenib alone.
The POLAR Study: Pembrolizumab With Olaparib for Metastatic Pancreatic Cancer
Переглядів 9728 днів тому
Dr. Wungki Park gives an overview of the POLAR study, which examined the use of olaparib with pembrolizumab for patients with metastatic pancreatic cancer. The study investigated the combination in patients with non-core homologous recombination deficiency, and in those who demonstrated high response to platinum therapy.
ASP3082 in Patients With Solid Tumors and KRAS G12D Mutations
Переглядів 14828 днів тому
At ESMO Congress 2024, we met with Wungki Park, MD, MS, of Memorial Sloan Kettering Cancer Center, to discuss his trial on the use of ASP3082 in patients with solid tumors. The investigational drug has been analyzed in previously treated patients with KRAS G12D mutations.
Preoperative CRT Versus Perioperative CT for Gastric Cancer: The TOPGEAR Study
Переглядів 175Місяць тому
At the ESMO Congress 2024, Trevor Leong, MD, of Peter MacCallum Cancer Centre, showcases the highly anticipated results of the TOPGEAR study, which sought to determine whether the addition of preoperative chemoradiotherapy to perioperative chemotherapy would improve pathological complete response rates and overall survival compared to perioperative chemotherapy alone in patients with resectable...
ESMO24 GI Review: LEAP-012, TOPGEAR, and EMERALD
Переглядів 134Місяць тому
At ESMO 2024, Zev Wainberg, MD, from the University of California, Los Angeles, reviews the ESMO data on gastrointestinal malignancies and notes that it is now unclear who should receive radiation before surgery. He discusses trials in gastric cancer, hepatocellular carcinoma, and pancreatic cancer. Dr Wainberg is optimistic about the future of the tricky endpoint that progression-free survival...
LEAP-012: PFS With Pembrolizumab, Levatinib, and TACE vs TACE Alone
Переглядів 86Місяць тому
At ESMO 2024, Josep Llovet, MD, PhD, from the Icahn School of Medicine at Mount Sinai, discusses LEAP-012, which compared TACE alone with pembrolizumab, lenvatinib, and TACE for the treatment of unresectable, non-metastatic hepatocellular carcinoma. Notable data from this study include: pembrolizumab plus lenvatinib in combination with TACE reduced the risk for disease progression or death by 3...
DESTINY-Gastric03: Analyzing Trastuzumab Deruxtecan for Gastric and GEJ Cancers
Переглядів 110Місяць тому
At the ESMO Congress 2024, Yelena Janjigian, MD, of Memorial Sloan Kettering Cancer Center, shares an overview of the DESTINY-Gastric03 study and the history of trastuzumab deruxtecan (T-Dxd) for gastric and GEJ cancers. She addresses how T-Dxd monotherapy compares to its use with fluoropyrimidine and pembrolizumab, the next steps for researching this treatment and whether more testing is warra...
Determining the Optimal Colorectal Cancer Screening Option for Patients
Переглядів 71Місяць тому
William M. Grady, MD, of Fred Hutchinson Cancer Center, continues his break down of the colorectal cancer screening landscape, offering his thoughts on whether colonoscopy, stool-based tests, or blood-based tests will be integrated into screening guidelines (or given on a patient-by-patient basis). Dr. Grady concludes with a note on the continued direction of the ECLIPSE study for the Shield test.
Colorectal Cancer Screening: Shield and the ECLIPSE Study
Переглядів 49Місяць тому
William M. Grady, MD, of Fred Hutchinson Cancer Center, shares an overview of the ECLIPSE study and its significance in colorectal cancer screening, including the key findings that led to the FDA approval of the Shield test. Dr. Grady also explains in detail how the Shield test differs from existing colorectal cancer screening methods, such as colonoscopy and stool-based tests.
Top 5 Uses of Artificial Intelligence in GI Medical Oncology
Переглядів 102Місяць тому
GI Oncology Now Advisory Board member Christopher Lieu, MD, of University of Colorado Cancer Center, breaks down his top uses of AI in gastrointestinal medical oncology today, as well as their projected applicability in the near future. Dr. Lieu lists clinical trial design and patient selection, risk stratification, and other uses.
First-line Atezolizumab With Bevacizumab for HCC
Переглядів 1082 місяці тому
Amit Mahipal, MD, of University Hospitals discusses a recent study on atezolizumab plus bevacizumab as a first-line treatment for hepatocellular carcinoma. Dr. Mahipal describes the benefits of the combination, and reviews the differences between Child-Pugh and ALBI scores for patients, as well as the disparities that affect certain patient populations with HCC. 00:00 Benefits of Atezo/Bev 01:3...
TGF-β Signaling Pathway Disruption for Effective Treatment of HCC With NK Cells
Переглядів 522 місяці тому
Dan Kaufman, MD, PhD, professor of medicine at @UCSDHealth, discusses recent research on transforming growth factor beta (TGF-β) and how it is linked to the development of hepatocellular carcinoma (HCC). TGF-β inhibition works in conjunction with anti-HCC chimeric antigen receptors (CARs) to promote anti-tumor activity, and enables the expression of anti-HCC CARs on iPSC-NK cells. 00:00 TGF-β a...
Utilizing TAS102 and Regorafenib for Future Studies
Переглядів 372 місяці тому
Dr. Wafik El-Deiry of @brownuniversity continues his discussion of regorafenib plus TAS-102 for colorectal cancer, focusing on the potential use of this combination in future gastrointestinal cancer studies. He also expands on how the combination reduces ALDH1 expression in HT29 cells, and the benefits of targeting ERK1/2 and STAT3 activation. 00:00 Synergy in Liver Cancer Cells 01:43 Inducing ...
Regorafenib and TAS102 for GI Cancers
Переглядів 632 місяці тому
Wafik El-Deiry, MD, PhD, FACP, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, @brownuniversity, discusses his study on regorafenib with TAS102 for multiple gastrointestinal cancers, particularly colorectal cancer. He elaborates on the synergistic activity seen in the combination when used in cancer cells, as well as the vulnerability of colorectal cancer cells when e...
Dr. Joel Rubenstein on New AGA Guideline: Endoscopic Eradication Therapy for Barrett's Esophagus
Переглядів 582 місяці тому
Dr. Joel Rubenstein on New AGA Guideline: Endoscopic Eradication Therapy for Barrett's Esophagus
Survival Outcomes of Neoadjuvant mFOLFIRINOX for Resectable PDAC
Переглядів 1442 місяці тому
Survival Outcomes of Neoadjuvant mFOLFIRINOX for Resectable PDAC
Examining the Lifetime Risk of Gastric Cancer in Patients With CDH1 Gene Variants
Переглядів 2913 місяці тому
Examining the Lifetime Risk of Gastric Cancer in Patients With CDH1 Gene Variants
Potential Benefits of Serum Fusion Transcripts in HCC
Переглядів 273 місяці тому
Potential Benefits of Serum Fusion Transcripts in HCC
Using Machine Learning Models to Diagnose, Monitor HCC
Переглядів 263 місяці тому
Using Machine Learning Models to Diagnose, Monitor HCC
Disparities in Biomarker Testing for Metastatic Colorectal Cancer
Переглядів 1733 місяці тому
Disparities in Biomarker Testing for Metastatic Colorectal Cancer
Anti-CCR8 Antibody Demonstrates Promising Results for Gastric Cancer
Переглядів 2673 місяці тому
Anti-CCR8 Antibody Demonstrates Promising Results for Gastric Cancer
Implications for Targeted Therapy: Genomic Profiling of USC Pancreatic Tumors
Переглядів 454 місяці тому
Implications for Targeted Therapy: Genomic Profiling of USC Pancreatic Tumors
SPOTLIGHT: Final OS Results for Zolbetuximab Plus mFOLFOX6 in Metastatic Gastric/GEJ Adenocarcinoma
Переглядів 2844 місяці тому
SPOTLIGHT: Final OS Results for Zolbetuximab Plus mFOLFOX6 in Metastatic Gastric/GEJ Adenocarcinoma
Future Directions in Colorectal Cancer Care
Переглядів 1204 місяці тому
Future Directions in Colorectal Cancer Care
Sequencing Novel Therapies in Colorectal Cancer
Переглядів 1824 місяці тому
Sequencing Novel Therapies in Colorectal Cancer
Incorporating ctDNA, Novel Therapies Into Practice for Colorectal Cancer
Переглядів 1874 місяці тому
Incorporating ctDNA, Novel Therapies Into Practice for Colorectal Cancer
Treatment Considerations for Oligometastatic Colorectal Cancer
Переглядів 3114 місяці тому
Treatment Considerations for Oligometastatic Colorectal Cancer
Targeted Therapies and Drivers for Treatment Choice in Colorectal Cancer
Переглядів 2774 місяці тому
Targeted Therapies and Drivers for Treatment Choice in Colorectal Cancer
Colorectal Cancer: Recent Changes in the Treatment Landscape
Переглядів 7204 місяці тому
Colorectal Cancer: Recent Changes in the Treatment Landscape
Thank you, you give me hope for my father.
Thank you, Grace-Ann, for creating this insightful and informative video.
You're welcome!
Signet ring cell adenocarcinoma concentrated in the right side, pelvic mets. 5 years out, 25 years old now. I have done FOLFOX, 30 rounds of radiation, and 3 tumour removal surgeries (LAR, bladder, ovary) Metastatic rectal adenocarcinoma, MMR proficient, RAS/BRAF/NTRK wild type, PIK3CA and TP53 mutations on somatic profiling What should my treatment plan be? Pllleeeese help me
Hi Dear.. I visited your UA-cam channel and found it needs a lot of updates. First of all your channel video SEO is very weak due to which your channel video views are not increasing. If you do SEO then your video will come first in the search list and your video views and subscribers will increase. Do you want to customize your channel?
😊 "Promosm"